Thambi Dorai

Thambi Dorai


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Journal of Urology
Verified
Journal Article
Closed access
TDThambi Dorai
Thambi Dorai
AFAndrew I. Fishman
Andrew I. Fishman
CDCheng Ding
Cheng Ding
IBInes Batinic-Haberle
Ines Batinic-Haberle
DGDavid S. Goldfarb
David S. Goldfarb
MGMichael Grasso
Michael Grasso
Extended warm ischemia during partial nephrectomy can lead to considerable renal injury. Using a rat model of renal ischemia we examined the ability of a unique renoprotective cocktail to ameliorate warm ischemia-reperfusion injury. A warm renal ischemia model was developed using 60 Sprague-Dawley® rats. The left renal artery was clamped for 40 minutes, followed by 48 hours of reperfusion. A renoprotective cocktail of a mixture of specific growth factors, mitochondria protecting biochemicals and Manganese-Porphyrin (MnTnHex-2-PyP(5+)) was given intramuscularly at -24, 0 and 24 hours after surgery. At 48 hours the 2 kidneys were harvested and examined with hematoxylin and eosin, and periodic acid-Schiff stains. Protein and gene expression were also analyzed to determine ischemia markers and the antioxidant response. Compared to ischemic controls, kidneys treated with the renoprotective cocktail showed significant reversal of morphological changes and a significant decrease in the specific ischemic markers lipocalin-2, mucin-1 and galectin-3. Quantitative reverse transcriptase-polymerase chain reaction revealed up-regulation of several antioxidant genes in treated animals. According to histopathological and several molecular measures our unique renoprotective cocktail mitigated ischemia-reperfusion injury.

18 December 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
TDThambi Dorai
Thambi Dorai
BDBhuvaneswari Dorai
Bhuvaneswari Dorai
JPJohn T. Pinto
John T. Pinto
MGMichael Grasso
Michael Grasso
Arthur J. CooperArthur J. Cooper
Arthur J. Cooper
Many tumors readily convert l-glutamine to α-ketoglutarate. This conversion is almost invariably described as involving deamidation of l-glutamine to l-glutamate followed by a transaminase (or dehydrogenase) reaction. However, mammalian tissues possess another pathway for conversion of l-glutamine to α-ketoglutarate, namely the glutaminase II pathway: l-Glutamine is transaminated to α-ketoglutaramate, which is then deamidated to α-ketoglutarate by ω-amidase. Here we show that glutamine transaminase and ω-amidase specific activities are high in normal rat prostate. Immunohistochemical analyses revealed that glutamine transaminase K (GTK) and ω-amidase are present in normal and cancerous human prostate and that expression of these enzymes increases in parallel with aggressiveness of the cancer cells. Our findings suggest that the glutaminase II pathway is important in providing anaplerotic carbon to the tricarboxylic acid (TCA) cycle, closing the methionine salvage pathway, and in the provision of citrate carbon in normal and cancerous prostate. Finally, our data also suggest that selective inhibitors of GTK and/or ω-amidase may be clinically important for treatment of prostate cancer. In conclusion, the demonstration of a prominent glutaminase II pathway in prostate cancer cells and increased expression of the pathway with increasing aggressiveness of tumor cells provides a new perspective on ‘glutamine addiction’ in cancers.

15 July 2018 in The Prostate
Verified
Journal Article
Closed access
PDF file
TDThambi Dorai
Thambi Dorai
ASAnkeeta Shah
Ankeeta Shah
FSFaith Summers
Faith Summers
RMRajamma Mathew
Rajamma Mathew
JHJing Huang
Jing Huang
JWJoseph M. Wu
Joseph M. Wu

1 May 2022 in Analytical Biochemistry
Verified
Journal Article
Closed access
Arthur J. CooperArthur J. Cooper
Arthur J. Cooper
TDThambi Dorai
Thambi Dorai
JPJohn T. Pinto
John T. Pinto
TDTravis T. Denton
Travis T. Denton